Logo

OLMA

Olema Pharmaceuticals, Inc.

OLMA

Olema Pharmaceuticals, Inc. • NASDAQ
$28.36 ▲ 0.85% (+0.24)
Market Cap $1.95 B
52w High $29.51
52w Low $2.86
Dividend Yield 0%
P/E -16.11
Volume 69.53K
Outstanding Shares 68.66M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $45.877M ▼ $-42.217M ▲ 0% $-0.49 ▲ $-42.174M ▲
Q2-2025 $0 $47.864M ▲ $-43.784M ▼ 0% $-0.51 ▼ $-47.732M ▼
Q1-2025 $0 $34.873M ▼ $-30.389M ▲ 0% $-0.36 ▲ $-34.745M ▲
Q4-2024 $0 $36.768M ▼ $-33.567M ▲ 0% $-0.57 ▲ $-36.652M ▲
Q3-2024 $0 $37.621M $-34.555M 0% $-0.6 $-37.526M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $328.96M ▼ $352.453M ▼ $44.965M ▲ $307.488M ▼
Q2-2025 $361.913M ▼ $382.002M ▼ $36.766M ▲ $345.236M ▼
Q1-2025 $392.707M ▼ $409.639M ▼ $26.187M ▼ $383.452M ▼
Q4-2024 $434.086M ▲ $450.979M ▲ $42.015M ▲ $408.964M ▲
Q3-2024 $214.763M $230.173M $31.262M $198.911M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-42.217M ▲ $-34.527M ▼ $17.273M ▼ $41K ▲ $-17.213M ▼ $-34.527M ▼
Q2-2025 $-43.784M ▼ $-29.883M ▲ $34.234M ▲ $-2.518M ▼ $1.833M ▲ $-29.883M ▲
Q1-2025 $-30.389M ▲ $-43.979M ▼ $-45.083M ▲ $222K ▼ $-88.84M ▼ $-43.979M ▼
Q4-2024 $-33.567M ▲ $-26.284M ▲ $-114.424M ▼ $244.3M ▲ $103.592M ▲ $-26.284M ▲
Q3-2024 $-34.555M $-27.016M $45.92M $92K $18.996M $-27.016M

Five-Year Company Overview

Income Statement

Income Statement Olema is still a pure research-stage biotech with no product revenue yet, so its income statement is entirely driven by research and operating costs. Losses have been consistent and sizeable as the company has advanced clinical trials and expanded its pipeline. The pattern is what you would expect from a clinical‑stage oncology company: rising spending on trials, people, and infrastructure, offset by no commercial income. That means current financial performance mainly reflects investment in future potential rather than ongoing business strength.

Balance Sheet

Balance Sheet The balance sheet is equity‑funded and relatively simple. The company holds a meaningful cash position compared with its size, and it carries no financial debt, which lowers balance‑sheet risk. Assets are dominated by cash and equivalents, with limited hard assets. After a period of cash drawdown, the company appears to have refreshed its capital base recently, which strengthens near‑term flexibility but does not remove the need for future funding if trials are prolonged or expanded.

Cash Flow

Cash Flow Cash flows are consistently negative, driven almost entirely by operating activities related to R&D and overhead. There is effectively no spending on capital equipment, so the cash burn is mostly tied to trial costs and staff rather than large fixed investments. Free cash flow tracks closely with operating cash flow, underscoring that this is a classic “cash‑burning” biotech. Sustainability of this burn rate depends on access to capital markets or partnerships, since the business does not yet self‑fund.

Competitive Edge

Competitive Edge Olema’s competitive position rests on a focused bet in a crowded but attractive niche: endocrine‑driven breast cancer. Its lead drug, palazestrant, is differentiated by a dual mechanism that both blocks and degrades the estrogen receptor, with the added advantages of oral dosing and potential activity in resistant, mutation‑positive disease and possibly in brain metastases. That said, the oral SERD field is busy, with several large pharma competitors and some already‑approved agents, so Olema must show clearly superior or broader benefits to stand out. Strategic collaborations with big pharma for combination trials and fast‑track status add credibility, but the company remains highly dependent on one core asset and on successfully navigating intense competition.

Innovation and R&D

Innovation and R&D Innovation is the core strength here. Olema has built deep expertise around estrogen‑receptor biology and is now layering on an epigenetic program with its KAT6 inhibitor, giving it a focused but expanding oncology platform. The lead program is already in pivotal Phase 3 studies in both later‑line and first‑line metastatic breast cancer, which signals a mature and ambitious R&D strategy. The newer KAT6 program is earlier stage but broadens potential applications across multiple solid tumors and offers future combo opportunities with palazestrant. Overall, R&D is high‑risk but scientifically compelling, with clear upcoming data catalysts that will strongly influence the company’s trajectory.

Summary

Olema is a classic clinical‑stage oncology company: no revenue, steady losses, negative cash flow, and a balance sheet funded by equity rather than debt. The financials reflect deliberate investment in a high‑risk, high‑reward pipeline rather than operational performance. Its story is dominated by one late‑stage breast‑cancer drug that could be meaningfully differentiated but must compete in a crowded field, plus a promising early epigenetic program. Strengths include scientific depth, a clean balance sheet, credible partnerships, and regulatory tailwinds. Key risks center on clinical trial outcomes, competitive pressure from larger players, the need for ongoing external funding, and the binary nature of pivotal data over the next few years.

NEWS

November 21, 2025 · 4:30 PM UTC

Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference

Read more

November 20, 2025 · 4:01 PM UTC

Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Read more

November 18, 2025 · 4:51 PM UTC

Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Read more

November 10, 2025 · 7:00 AM UTC

Olema Oncology Reports Third Quarter 2025 Financial and Operating Results

Read more

November 4, 2025 · 4:30 PM UTC

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more